Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPB1 | P04792 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4087059 | 0.93 | HSPB1 (0.43) | HSPB1RAB9ANPC1GPR35ALDH1A1 | |
| SCHEMBL4087052 | 0.93 | HSPB1 (0.43) | HSPB1RAB9ANPC1GPR35ALDH1A1 | |
| SCHEMBL27479661 | 0.84 | HSPB1 (0.48) | HSPB1RAB9ANPC1GPR35ALDH1A1 | |
| SCHEMBL2012344 | 0.83 | HSPB1 (0.48) | HSPB1RAB9AGPR35ALDH1A1MEN1 | |
| SCHEMBL28920607 | 0.83 | HSPB1 (0.47) | HSPB1RAB9ANPC1GPR35ALDH1A1 | |
| SCHEMBL4090307 | 0.83 | HSPB1 (0.47) | HSPB1RAB9AGPR35ALDH1A1MEN1 | |
| SCHEMBL15763944 | 0.81 | KMT2A (0.47) | RAB9ANPC1ALDH1A1KMT2APOLB | |
| SCHEMBL16388747 | 0.80 | SMN1; SMN2 (0.45) | HSPB1RAB9AALDH1A1KDM4EMEN1 | |
| SCHEMBL28478554 | 0.79 | HSPB1 (0.43) | HSPB1RAB9ANPC1GPR35ALDH1A1 | |
| SCHEMBL27668224 | 0.77 | ALDH1A1 (0.48) | HSPB1RAB9ANPC1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099164-A1 | Phenylaminopropanol Derivatives and Methods of Their Use | WYETH (US) | 2009-04-16 | — | — | US | disclosed |
| US-7517899-B2 | Phenylaminopropanol derivatives and methods of their use | WYETH (US) | 2009-04-14 | — | — | US | disclosed |
| US-20090093469-A1 | Phenylaminopropanol Derivatives and Methods of Their Use | WYETH (US) | 2009-04-09 | — | — | US | disclosed |
| EP-1732887-B1 | 1-(1H-INDOL-1-YL)-3-(4-METHYLPIPERAZIN-1-YL)-1-PHENYL PROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE NOREPINEPHRINE (NE) AND THE SEROTONINE (5-HT) ACTIVITY AND THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | WYETH CORP (US) | 2008-01-09 | — | — | EP | disclosed |
| EP-1732887-A1 | 1-(1H-INDOL-1-YL)-3-(4-METHYLPIPERAZIN-1-YL)-1-PHENYL PROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE NOREPINEPHRINE (NE) AND THE SEROTONINE (5-HT) ACTIVITY AND THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | Wyeth (US) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005097744-A1 | 1-(1H-INDOL-1-YL)-3-(4-METHYLPIPERAZIN-1-YL)-1-PHENYL PROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE NOREPINEPHRINE (NE) AND THE SEROTONINE (5-HT) ACTIVITY AND THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | WYETH (US) | 2005-10-20 | — | — | WO | disclosed |
| US-20050222148-A1 | Phenylaminopropanol derivatives and methods of their use | WYETH (US) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099164-A1 | Phenylaminopropanol Derivatives and Methods of Their Use | PAH, PNMT, COMT | HSPB1 2742/4885RAB9A 2956/4885NPC1 3723/4885 |
| US-20050222148-A1 | Phenylaminopropanol derivatives and methods of their use | PAH, PNMT, COMT | HSPB1 2742/4885RAB9A 2956/4885NPC1 3723/4885 |
| US-20090093469-A1 | Phenylaminopropanol Derivatives and Methods of Their Use | PAH, PNMT, COMT | HSPB1 2742/4885RAB9A 2956/4885NPC1 3723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.